Bo Piela News
-
Shelbyzyme LLC, the owner of a patent used to treat organ-destroying Fabry disease, won $50 million from Genzyme Corp. after a jury trial.
-
Shelbyzyme LLC, the owner of a patent used to treat organ-destroying Fabry disease, won $50 million from Genzyme Corp. after a jury trial.
-
Sanofi-Aventis SA ’s three-month effort to acquire Genzyme Corp. took a more contentious turn as the companies’ chief executive officers offered conflicting accounts of their face-to-face meeting last month.
-
Home to more foreclosures than 47 U.S. states, Florida sought to clear out its backlog with a system of special court hearings that dispensed with cases quickly, sometimes in less than a minute, Bloomberg News’ David McLaughlin reports.
-
Genzyme Corp.’s chief executive officer, Henri A. Termeer , will leave his post of 26 years after Sanofi-Aventis SA closes its $20.1 billion purchase of his company. He may not be out of a job for long.
-
Sanofi-Aventis SA Chief Executive Chris Viehbacher provided a possible price range of $69 to $80 a share to buy Genzyme Corp. at a Sept. 20 meeting with the U.S. company’s chief, Genzyme said.
-
Genzyme Corp. agreed to give Sanofi- Aventis SA access to confidential information, bringing the companies a step closer to a deal five months after the French drugmaker offered to buy Genzyme for $18.5 billion.
-
Genzyme Corp. , the biotechnology company being pursued in a hostile takeover by French drugmaker Sanofi-Aventis SA , expects to meet a Nov. 28 deadline to move finishing and filling operations for U.S. products out of its Allston, Massachusetts plant.
-
Options contracts on Genzyme Corp.’s multiple sclerosis drug would decrease Sanofi-Aventis SA’s cost by as much as $1.6 billion in a takeover of the world’s largest maker of treatments for rare genetic diseases.
-
Sanofi-Aventis SA is still looking at Genzyme Corp. ’s books for a potential $19.2 billion acquisition of the U.S. biotechnology company.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page